TRACE4OC

TRACE4OC is indicated for women at risk of ovarian cancer on the recommendation of gynecology specialists. Physicians with expertise with pelvic US can use TRACEOC to support the reporting on US-detected adnexal masses investigations in these subjects. Specialists in gynecology can use TRACE4OC as an aid to diagnosis. TRACE4OC software provides the subject level of risk (very low risk or medium-high risk) of being affected with ovarian cancer at the date of the TRACE4OC-processed US investigation of an adnexal mass, combined with the serum level test for Cancer Antigen 125 (CA-125), performed no earlier than and no later than one month from the US study, and with the current woman’s menopausal state (premenopausal or post menopause). However, it should be noted that DeepTrace Technologies S.R.L. considers TRACE4OC as a support to gynecology specialists in their diagnosis, and as a support to physicians with expertise with pelvic US in their reporting on adnexal masses. These medical professionals keep the final decision-making responsibility.